Navigation Links
Phase II Medical Manufacturing Selects IQMS for ERP Solution
Date:2/5/2008

EnterpriseIQ Supports Device Manufacturer's Continued Growth and Compliance

PASO ROBLES, Calif., Feb. 5 /PRNewswire/ -- IQMS, a leader in the design and development of Enterprise Resource Planning (ERP) software, has been selected by Phase II Medical Manufacturing for its comprehensive ERP software, EnterpriseIQ. As Phase II continues to excel in the medical device manufacturing industry, so does the level of visibility needed to manage the company's growth. Phase II is committed to continual quality and compliance as an FDA-approved, and ISO 9001:2000 and ISO 13485:2003 certified manufacturer. EnterpriseIQ supports this effort by enabling the company to best manage time-to-market and traceability, and sustain continued growth and conformance.

"Rapid expansion was taxing our spread-sheet based system," says Adam Prime, president of Phase II. "To remain competitive, we needed a robust ERP system that could grow with us and cost-effectively manage our quality and compliance issues. EnterpriseIQ was the perfect fit. With modules like Quality Medical, RealTime Machine Monitoring, and Customer Relationship Management, we now have more control over our core business data, and because EnterpriseIQ is scalable we are well prepared for long-term growth and success."

The Quality Medical and Device History Record (DHR) modules are included in EnterpriseIQ to address the unique needs of medical manufacturers. These modules facilitate better internal communication and collaboration while ensuring quality standards compliance with capabilities such as: adherence to TS13485 and ISO 9001 standards, and CFR and FDA requirements; up-front risk assessment; electronic signature and document control; complete audit trail of manufacturing processes; comprehensive Corrective Action/Preventive Action (CAPA); and non-conforming product review and tracking. With EnterpriseIQ, medical device manufacturers can streamline operations and product development to gain a stronger competitive advantage.

"Medical device manufacturers operate in one of the world's most highly regulated industries," says Randy Flamm, president and founder of IQMS. "IQMS is committed to helping manufacturers like Phase II succeed in their ever-changing and complex industry. We've tailored EnterpriseIQ specifically to make their jobs easier. That's why so many Class 1, 2 and 3 device manufacturers rely on IQMS as their single-source ERP provider. We are thrilled Phase II has joined them, and we look forward to helping Phase II accelerate their success for many years to come."

About Phase II

Founded in 1995 to serve the single-use medical product and device industry, Phase II Medical Manufacturing now provides design, development, manufacturing, packaging, shipping, and sterilization services to its customers. FDA registration, Canadian licensing, and ISO 9001:2000 and ISO 13485:2003 certification are maintained to ensure that current U.S. and international standards are satisfied. Phase II works closely with clients on a regular basis to ensure all devices meet or exceed specifications, and its commitment and dedication to customers is unmatched in the industry.

About IQMS

Since 1989, IQMS has been a pioneer in the design and development of ERP software for repetitive, process and discrete manufacturing industries. Today, IQMS provides leading real-time manufacturing, accounting, machine monitoring, quality control, supply chain, CRM and eBusiness solutions to the automotive, medical, packaging, consumer goods and other manufacturing markets. The only complete, single-source enterprise software solution, EnterpriseIQ offers real-time front office, accounting, manufacturing and supply chain management in a single database. With offices across North America, Europe and Asia, IQMS serves manufacturers around the world. Visit IQMS online at http://www.iqms.com.

IQMS and EnterpriseIQ are trademarks of IQMS. All other brand and product names are the trademarks of their respective companies.


'/>"/>
SOURCE IQMS
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ovation further advances development pipeline with new phase III epilepsy study
2. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
3. Mannatech Launches Phase One of New Sales and Training Tools
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Manic phase of bipolar disorder benefits from breast cancer medication
6. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
7. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
8. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Bioclinica® ... sponsors and CROs to speed clinical development, has released the industry’s only ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management together ...
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
(Date:4/25/2017)... ... 2017 , ... As pharmaceutical companies are held to increasingly ... innovation in drug formulation and manufacturing. CoreRx offers its clients more than ... support of their development and manufacturing goals. , The company was created ...
(Date:4/25/2017)... Scotch Plains, NJ (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD ... with the treatment of acute or chronic problems, I focus on preventative care with all ... patient. If you have any questions, always feel free to contact my office and my ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 Global Surgical Drainage Device ... tubes used to remove excess liquid and air. The ... urine, bile or lymph. Surgical drains are used in ... as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. ... to prevent accumulation of fluid e.g. blood or pus. ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology: